Quarterly report pursuant to Section 13 or 15(d)

License Agreements - Additional Information (Detail)

v3.19.1
License Agreements - Additional Information (Detail)
1 Months Ended 33 Months Ended
Jan. 22, 2018
USD ($)
May 14, 2015
Jul. 31, 2016
USD ($)
Mar. 31, 2019
USD ($)
g
Sopharma [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
License agreement expiry date   May 26, 2029    
University of Bristol [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Maximum amount payable under license agreement, tied to milestones     $ 3,200,000  
Payments under license agreement       $ 125,000
License agreement expiry     2036-07  
Volume of cytisine provided as an initial contribution | g       100
University of Bristol [Member] | Amendment to the University of Bristol License Agreement [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Maximum amount payable under license agreement, tied to milestones $ 1,700,000      
Payments under license agreement $ 37,500      
University of Bristol [Member] | Minimum [Member] | License Agreement [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Patent expiry date     Feb. 05, 2036